Ipamorelin vs MK-677: Which Better Comparison | Real Peptides
Research published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 (ibutamoren) elevated mean 24-hour growth hormone levels by 97% compared to placebo. But also increased cortisol by 32% and fasting glucose by 8–12 mg/dL. Ipamorelin, a
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 (ibutamoren) elevated mean 24-hour growth hormone levels by 97% compared to placebo. But also increased cortisol by 32% and fasting glucose by 8–12 mg/dL. Ipamorelin, a selective growth hormone secretagogue peptide (GHSP), produced comparable IGF-1 elevation without measurable cortisol or prolactin disruption across multiple Phase II trials. The mechanism distinguishes them entirely: MK-677 is an orally bioavailable ghrelin receptor agonist that sustains GH secretion around the clock, while ipamorelin is an injectable pentapeptide that triggers discrete GH pulses mimicking endogenous somatotroph activity.
- Our team has reviewed peptide protocols across hundreds of research applications. The ipamorelin vs MK-677 which better comparison isn't about efficacy. Both elevate IGF-1 reliably. It's about secondary endocrine effects, administration logistics, and protocol objectives that most comparison guides ignore entirely.
- What's the core difference between ipamorelin and MK-677 for research applications?
- Ipamorelin is a selective GHRP-class peptide administered via subcutaneous injection 1–3 times daily, producing short-duration GH pulses (90–120 minutes) without affecting cortisol, prolactin, or ACTH. MK-677 is an orally active ghrelin mimetic taken once daily that sustains elevated GH and IGF-1 for 24 hours but increases appetite signaling, cortisol, and glucose. Ipamorelin suits protocols requiring precise timing and minimal metabolic disruption; MK-677 fits continuous-elevation models where convenience outweighs secondary hormone effects.